UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

FORM 6-K

Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934

Date of Report: September 8, 2016 Commission File Number: 001-36891

Cellectis S.A.

(Exact Name of registrant as specified in its charter)

8, rue de la Croix Jarry 75013 Paris, France +33 1 81 69 16 00 <u>(Address of principal executive office)</u>

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F 🗹 Form 40-F 🗌

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

EXHIBIT INDEX

Exhibit <u>Title</u>

÷

99.1 Press release, dated September 8, 2016.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

CELLECTIS S.A.

(Registrant)

September 8, 2016

By: /s/ André Choulika

André Choulika Chief Executive Officer

Cellectis Reports 2nd Quarter and First Half Year 2016 Financial Results

- First patient dosed in phase 1 clinical trial for UCART19

- UCART 123 manufacturing ongoing

- Strong cash position of \$300 million¹ (€270 million) as of June 30, 2016

- Revenues and other income of \$20 million² (€18 million) in the 2nd quarter of 2016

- Adjusted income attributable to shareholders³ of \$9 million² (€8 million) in the 2nd quarter of 2016

NEW YORK--(BUSINESS WIRE)--September 8, 2016--Regulatory News:

Cellectis S.A. (Paris:ALCLS) (NASDAQ:CLLS) (Alternext: ALCLS - Nasdaq: CLLS), a biopharmaceutical company focused on developing immunotherapies based on gene edited CAR T-cells (UCART), today announced its results for the three-month period ended June 30, 2016 and for the six-month period ended June 30, 2016.

Recent Corporate Highlights

Cellectis

• A Phase I study of UCART19 in pediatric acute B lymphoblastic leukemia (B-ALL) was initiated at the University College of London (UCL), with the first dose administered to a patient in June 2016. This UCART19 clinical trial is sponsored by Servier in close collaboration with Pfizer.

- Cellectis employees presented important scientific presentations:
 - An intrinsic safeguard Chimeric Antigen Receptor architecture for T-cell immunotherapy, presented by Julien Valton at ASCO, Chicago;
 - Allogeneic TCRα/CD38 double knockout T-cells bearing an anti-CD38 Chimeric Antigen Receptor (CAR): an improved immunotherapy for the treatment of T-cell acute lymphoblastic leukemia (T-ALL) and multiple myeloma (MM), presented by Mathilde Dusseaux at EHA, Copenhagen, Denmark.
- The MIT Technology Review has named the Company on its Annual List of 50 Smartest Companies for the second year in a row.
- Cellectis has been selected as a 2016 World Economic Forum Technology Pioneer, a credential that is awarded annually to the most innovative and impactful companies developing new technologies around the world.

¹ Euro-US Dollar exchange rate as of June 30, 2016: 1.1102

² Euro-US Dollar average exchange rate for the 2nd quarter 2016: 1.1293

³ See the section related to the reconciliation of gaap to non-gaap net income. GAAP Net Loss attributable to shareholders amounts to \$7 million ($\in 6$ million) in the 2nd quarter of 2016

Calyxt – Cellectis' plant science subsidiary

- Appointment of former Monsanto Corporation executive Federico A. Tripodi to the role of Chief Executive Officer, a key hire for the execution of the commercial business plan and market launch of lead programs.
- Completed the expansion of its high-oleic / no-trans-fat (HO) soybean variety in Argentina, as part of its counter-season seed production. Thirty tons of HO soybean seeds have been shipped to production sites in the United States for further expansion, in preparation for an initial commercial launch expected in 2018.
- Calyxt hosted an R&D Day in New York City on May 26. Speakers reviewed advancements made in the plant science community with a focus on Calyxt's plant engineering platform. Additionally, management provided an overview of Calyxt's crop programs.

Financial Results

Cellectis' consolidated financial statements have been prepared in accordance with International Financial Reporting Standards, or IFRS, as issued by the International Accounting Standards Board ("GAAP").

Second Quarter 2016 Financial Results

Cash: As of June 30, 2016 Cellectis had €269.7 million in total cash, cash equivalents and current financial assets compared to €276.5 million as of March 31, 2016. This decrease of €6.8 million notably reflects (i) the net cash flows used in operating activities of €7.6 million and (ii) fixed assets expenditure of €2.4 million. The change was also attributable to the unrealized positive translation effect of exchange rate fluctuations on our U.S. dollar cash, cash equivalents and current financial assets of €5.8 million.

Revenues and Other Income: During the quarters ended June 30, 2015 and 2016, we recorded $\in 8.0$ million and $\in 18.1$ million, respectively, in revenues and other income. This is mainly due to the increase of (i) $\in 8.6$ million in collaboration revenues, notably due to the achievement of two milestones under our collaboration agreement with Servier and (ii) $\in 1.5$ million in research tax credit.

Total Operating Expenses and Other Operating Income: Total operating expenses and other operating income for the second quarter of 2016 were €28.2 million, compared to €20.1 million for the second quarter of 2015. The non-cash stock-based compensation expenses included in these amounts were €14.4 million and €7.1 million, respectively.

R&D Expenses: For the quarters ended June 30, 2015 and 2016, research and development expenses increased by €6.7 million from €12.8 million in 2015 to €19.5 million in 2016.Personnel expenses increased by €2.4 million from €9.3 million in 2015 to €11.6 million in 2016, notably due to a €0.5 million increase in wages and salaries, and a €4.5 million increase in non-cash stock based compensation expense, partly offset by a €2.6 million decrease in social charges on stock options and free share grants. Purchases and external expenses increased by €4.3 million from €3.2 million in 2015 to €7.5 million in 2016, due to increased expenses related to innovation and platform development, including payments to third parties participating in product development, purchases of biological raw materials and expenses associated with the use of laboratories and other facilities.

SG&A Expenses: During the quarters ended June 30, 2015 and 2016, we recorded €6.9 million and €8.6 million, respectively, of selling, general and administrative expenses. The increase of €1.7 million primarily reflects (i) an increase of €1.9 million in personnel expenses from €4.6 million to €6.5 million, attributable, among other things, to an increase of €2.7 million of non-cash stock-based compensation expense, partly offset by a decrease of €0.9 million of social charges on stock options and free share grants, and (ii) a decrease of €0.3 million in purchases and external expenses.

Financial Gain (Loss): The financial loss was ≤ 10.0 million for the second quarter of 2015 compared with a financial gain of ≤ 3.8 million for the second quarter of 2016. The change in financial result was primarily attributable to the effect of exchange rate fluctuations on our U.S. dollar cash and cash equivalent accounts.

Net Income (Loss) Attributable to Shareholders of Cellectis: During the three months ended June 30, 2015 and 2016, we recorded a net loss of €22.2 million (or €0.63 per share on both a basic and a diluted basis) and net loss of €6.3 million (or €0.18 per share on both a basic and a diluted basis), respectively. Adjusted income attributable to shareholders of Cellectis for the second quarter of 2016 was €8.1 million (€0.23 per share on both a basic and a diluted basis) compared to Adjusted loss attributable to shareholders of Cellectis of €15.0 million (€0.43 per share on both a basic and a diluted basis), for the second quarter of 2015. Adjusted income (loss) attributable to shareholders of Cellectis for the second quarter of 2016 and 2015 excludes non-cash stockbased compensation expense of €14.4 million and €7.2 million, respectively. Please see "Note Regarding Use of Non-GAAP Financial Measures" for reconciliation of GAAP net income (loss) attributable to shareholders of Cellectis to Adjusted income (loss) attributable to shareholders of Cellectis.

First Half Year 2016 Financial Results

Cash: As of June 30, 2016 Cellectis had €269.7 million in total cash, cash equivalents and current financial assets compared to €314.2 million as of December 31, 2015. This decrease of €44.5 million was primarily driven by (i) €27.2 million of cash used in operating activities in connection with the initiation of industrial Good Manufacturing Practice ("GMP") production of UCART123, increased expenses in materials required of GMP production and a payment of €7.2 million of value added taxes related to proceeds received in the fourth quarter of 2015 from Servier, and (ii) €10.8 million of cash used in investment activities, primarily through Calyxt's land acquisition and greenhouse construction in an aggregate amount of €8.9 million. The decrease was also partially attributable to the negative unrealized translation effect of exchange rate fluctuations on our U.S. dollar cash, cash equivalents and current financial assets accounts of €5.8 million.

Cellectis expects that its cash, cash equivalents and Current financial assets of €269.7 million as of June 30, 2016 will be sufficient to fund its current operations through the end of 2018.

Revenues and Other Income: During the six months ended June 30, 2015 and 2016, we recorded \pounds 17.2 million and \pounds 27.6 million, respectively, in revenues and other income. This is mainly due to the increase of (i) \pounds 7.1 million in collaboration revenues notably due to the achievement of two milestones under our collaboration agreement with Servier and (ii) \pounds 3.4 million in research tax credit.

Total Operating Expenses and Other Operating Income: Total operating expenses and other operating income for the first half of 2016 were \in 58.1 million, compared to \notin 32.9 million for the first half of 2015. The non-cash stock-based compensation expenses included in these amounts were \notin 27.8 million and \notin 8.0 million, respectively.

R&D Expenses: For the six months ended June 30, 2015 and 2016, research and development expenses increased by €18.2 million from €20.2 million in 2015 to €38.4 million in 2016. Personnel expenses increased by €9.5 million from €13.9 million in 2015 to €38.4 million increase in wages and salaries, and a €11.6 million increase in non-cash stock based compensation expense, partly offset by a €3.5 million decrease in social charges on stock options and free share grants. Purchases and external expenses increased by €8.5 million from €5.7 million in 2015 to €14.2 million in 2016, due to increased expenses related to innovation and platform development, including payments to third parties participating in product development, purchases of biological raw materials and expenses associated with the use of laboratories and other facilities.

SG&A Expenses: During the six months ended June 30, 2015 and 2016, we recorded €12.2 million and €19.2 million, respectively, of selling, general and administrative expenses. The increase of €6.9 million primarily reflects (i) an increase of €6.5 million in personnel expenses from €8.3 million to €14.8 million, attributable, among other things, to an increase of €8.2 million of non-cash stock-based compensation expense, partly offset by a decrease of €2.0 million of social charges on stock options and free share grants, and (ii) an increase of €0.4 million in purchases and external expenses.

Financial Gain (Loss): The financial loss was €0.2 million for the first half year of 2015 compared with financial loss of €5.3 million for the first half year of 2016. The change in financial result was primarily attributable to the effect of exchange rate fluctuations on our U.S. dollar cash and cash equivalent accounts.

Net Income (Loss) Attributable to Shareholders of Cellectis: During the six months ended June 30, 2015 and 2016, we recorded a net loss of €16.0 million (or €0.48 per share on both a basic and a diluted basis) and a net loss of €35.7 million (or €1.01 per share on both a basic and diluted basis), respectively. Adjusted loss attributable to shareholders of Cellectis for the first half of 2016 was €7.9 million (€0.22 per share on both a basic and a diluted basis) compared to Adjusted income attributable to shareholders of Cellectis of €8.0 million (€0.24 per share on both a basic and a diluted basis), for the first half of 2015. Adjusted loss attributable to shareholders of Cellectis for the first half of 2016 and 2015 excludes a non-cash stock-based compensation expense of €27.8 million and €8.0 million, respectively. Please see "Note Regarding Use of Non-GAAP Financial Measures" for a reconciliation of GAAP net income (loss) attributable to shareholders of Cellectis.

CELLECTIS S.A.

STATEMENT OF CONSOLIDATED FINANCIAL POSITION (unaudited) (€ in thousands, except per share data)

December 31, 2015 June 30, 2016 Nan-current assets 956 1.268 Property, Data and equipment 5.043 15.198 Other non-current financial assets 946 749 Total non-current assets 6.844 17.213 Inventories and commutated costs on orders in process 1.98 1.255 Taba non-current assets 6.055 1.814 Oct and cost perviolents 6.055 1.814 Oct and cost perviolent and Current financial assets 3.14.228 2.2017.19 Total non-current assets 3.14.228 2.2017.19 Out and cost perviolent and Current financial assets 3.14.228 2.2017.19 Total Asset revivables 3.14.062 3.22.37 Total Asset revivables 3.17.59 1.757		As of	
Numerical assets 956 1 208 Property plant, and equipment 5 0.43 15 196 Other non-current financial assets 845 749 Total unon-current assets 6 844 17 213 Investories and accumulated costs on orders in process 158 125 Trade receivables 6 035 3 13 816 Subsidies receivables 9 102 13 324 Other current assets 31 4228 269 719 Trade receivables 31 4228 269 719 Total current assets 31 4218 30 5173 Total current assets 31 4218 30 5173 Total current assets 31 4218 30 5173 Total current assets 1759 1.767 Premiums related to the share capital 1.799 1.876 Premiums related to the share capital (163 11) (151 10) Retaide acrinings (102 544) <th></th> <th></th> <th>June 30, 2016</th>			June 30, 2016
Numerical assets 956 1 208 Property plant, and equipment 5 043 15 196 Other non-current financial assets 845 749 Total unon-current assets 6 884 17 213 Investories and accumulated costs on orders in process 158 125 Investories and accumulated costs on orders in process 9 102 13 324 Other court assets 9 102 13 324 Cuber court assets 31 4228 269 719 Total concrut assets 31 4228 269 719 Charl current assets 31 4228 269 719 Total current assets 31 4218 395 173 TOTAL ASSETS 31 4218 395 173 Stare capital 1 759 1 767 Premiums related to the share capital 1 759 1 767 Premiums related to the share capital 1 759 1 767 Premiums related to the share capital 1 759 1 767 Premiums related to the share capital 1 759 1 767 Premiums related to the share capital 1 759 1 767 <	ASSETS		
Property, plant, and equipment 5 0.43 15 196 Other non-current financial assets 845 7499 Tudal non-current assets 6 844 17 213 Current assets 158 125 Inventories and accumulated costs on orders in process 158 125 Turde receivables 6 003 13 041 Subsidies receivables 9 102 13 324 Other current assets 34 228 269 719 Tudal current financial assets 34 228 269 719 Tudal current assets 34 228 269 719 Tudal current assets 34 228 289 719 Tudal current assets 34 206 322 397 Detail current assets 34 206 242 387 Shareholders' equipt 1759 1.767 Share capital 1759 1.767 Promiums related to the share capital 1769 (16 31) (15 028) Current vitaslation adjustment (16 31) (15 028) (20 544) (35 719) Tudal shareholders' equity - Group Share 262 839 266 338 <td></td> <td></td> <td></td>			
Property, plant, and equipment 5 0.43 15 196 Other non-current financial assets 845 7499 Tudal non-current assets 6 884 17 213 Current assets 158 125 Inventories and accumulated costs on orders in process 158 125 Turde receivables 6 003 13 324 Other current assets 9 102 13 324 Other current assets 313 4238 269 719 Tudal current financial assets 313 4238 269 719 Tudal current assets 313 4218 305 173 TOTAL ASSETS 313 4216 305 173 Share capital 1759 1767 Promiums related to the share capital 1759 1767 Share capital 1759 1767 Promiums related to the share capital 1763 (157 623) Current vanishiton adjustment (16 61) (157 623) Net income (toss) (20 544) (35 719) Total shareholders' equity - Group Share 262 639 262 639 Non-current fiabilities	Intangible assets	956	1 268
Other inon-current financial assets 845 749 Total non-current assets 6844 17213 Current assets 6844 17213 Current assets 158 125 Trade receivables 6035 13816 Subsidies receivables 9102 13324 Other current assets 314233 269719 Total current assets 334218 305173 Total current assets 344 685 4.89 Share capital 1739 1767 Premiums related to the share capital 420 682 448 388 Treasury share reserve (184) (235) Current transition adjustment (1631) (1510) Retiande canings (20 544) (35719) Total babareholders' equity - Group Share 725 1166 Non-current liabilities 1921 2173 Total non-current			15 196
Current assets 158 125 Inventories and accumulated costs on orders in process 158 122 Trade receivables 6 0.03 13 816 Subsidies receivables 9 102 13 324 Other current assets 4 485 8 189 Cash and cash equivablent and Current financial assets 334 218 305 173 TOTAL ASSETS 334 1062 322 387 TOTAL ASSETS 341 062 322 387 Premiums related to the share capital 1759 1767 Premiums related to the share capital 408 (157 19) 1757 Currency transition adjustment (1631) (1510) Retined earnings (127 188) (157 189) Non-current liabilities 262 894 254 889 Non-current liabilities 66 38 Non-current liabilities 503 603 Current transci liabilities 503 603 Current tiabilities 503 665 Total shareholders' equity - Group Share 503 665 Total current liabilitites 50		845	749
Investories and accumulated costs on orders in process 158 125 Trade receivables 6 035 13 816 Subsidies receivables 9 102 13 324 Other current assets 4 665 8 189 Cash and cash equivalent and Current financial assets 334 218 305 173 TOTal current assets 334 218 305 173 TOTAL ASSETS 334 208 202 322 387 Share capital 1759 1767 Premiums related to the share capital 1759 1 Premiums related to the share capital 1759 1 Current yraslation adjustment (1 631) (1 510) Retained earnings (20 544) (35 719) Not-current itabilities 262 894 254 849 Non-current liabilities 6 6 38 Non-current liabilities 6 6 38 Non-current liabilities 6 611 11 324 Defered reveness and defered income 4 661 11 324 Defered reveness 6 611 11 324 Defered reveness and defered income	Total non-current assets	6 844	17 213
Trade receivables 6.035 13.816 Subsidies receivables 9.102 13.324 Other current assets 4.665 8.189 Cash and cash equivalent and Current financial assets 33.42.238 2269.719 TOTAL ASSETS 33.42.238 2322.387 ILIABILITIES Share capital 1.759 1.767 Premiums related to the share capital 1.759 1.767 Ourrency translation adjustment (16.31) (15.10) Retained earnings (16.31) (15.10) Net income (loss) (20.544) (35.719) Total shareholders' equity 262.894 254.853 Non-controlling interests 72.5 1.166 Non-current financial labilities 66 38 Non-current financial labilities 50.3 663 Current financial labilities 1.921	Current assets		
Subsidies receivables 9 102 13 324 Other current assets 3 4 685 6 189 Cash and cash equivalent and Current financial assets 3 34 218 3 305 173 TOTAL ASSETS 3 334 216 3 305 173 TOTAL ASSETS 3 34 218 3 305 173 Shareholders' equity 1 759 1 767 Premiums related to the share capital 1 759 1 767 Premiums related to the share capital 1 (1 510) (1 510) Retained earnings (1 37 180) (1 57 828) Not current labilities 2 26 284 224 895 Non-current labilities 2 26 3 6 19 2 26 6 024 Non-current labilities 6 6 38 38 Non-current labilities 1 921 2 173 Tade karenolders' equity - Group Share 5 053<	Inventories and accumulated costs on orders in process	158	125
Other current assets 4 685 8 189 Cash and cash equivalent and Current financial assets 314 228 269 719 Total current assets 334 218 305 173 TOTAL ASSETS 334 062 322 387 Charl current assets 334 062 322 387 Current labilities 1759 1767 Share capital 1759 1767 Pressury share reserve (1631) (1510) Current translotion adjustment (1631) (1510) Retained earnings (20 544) (235 719) Not controlling interests 725 1166 Total shareholders' equity Gold 9 256 024 Non-current fibalilities 263 619 256 024 Non-current fibalilities 663 38 Non-current fibalilities 503 663 Current fibalilities 1921 2173 Total shareholders' equity 1921 2173 Total shareholders' equity 661 38 Non-current fibalilities 503 663 <		6 035	13 816
Cash and cash equivalent and Current financial assets 314 238 269 719 Total current sests 334 218 335 719 TOTAL ASSETS 341 062 322 387 Shareholders' equity 1759 1767 Share capital 1759 1767 Premiums related to the share capital 420 682 448 388 Creasy share reserve (164) (239) Current y translation adjustment (1631) (1578 28) Non-current financial liabilities 262 834 254 853 Non-current financial liabilities 725 1166 Total shareholders' equity - Group Share 66 38 Non-current financial liabilities 663 36 Non-current financial liabilities 663 36 Current financial liabilities 1921 2173 Total shareholders' equity 1921 2173 Deferred revenues and deferred income 6611 1323 Ourcurrent liabilities 1921 2173 Total shifties 1921 2173 Deferred revenues and deferred	Subsidies receivables	9 102	13 324
Total current assets 334 218 335 213 TOTAL ASSETS 341 062 322 387 LIABILITIES 341 062 322 387 Share capital 1759 1767 Premiums related to the share capital 420 682 448 388 Treasury share reserve (184) (239) Currency translation adjustment (1510) (1510) Retained earnings (137 188) (137 828) Non-controlling interests 262 894 254 859 Non-controlling interests 275 5 1166 Total shareholders' equity 263 619 256 024 Non-current fibabilities 66 38 Non-current fibabilities 66 38 Current fibabilities 66 38 Current fibabilities 1921 2173 Tada payables 6 611 11324 Deferred revenues and deferred income 543 753 8447 Other current liabilities 953 847 Other current liabilities 953 847 Other current l			8 189
TOTAL ASSETS 341 062 322 387 LIABILITIES Share capital 1 759 1 767 Premiums related to the share capital 420 682 448 388 Treasury share reserve (184) (239) Currency translation adjustment (1631) (1510) Retained earnings (137 188) (157 828) Not income (loss) (20 544) (257 199) Total shareholders' equity 263 619 256 024 Non-current liabilities 725 1 166 Non-current financial liabilities 66 38 Non-current financial liabilities 663 36 Current financial liabilities 503 603 Current financial liabilities 1 1 321 2 173 Trade payables 6 611 11 1 324 Deferred revenues and deferred income 54 758 44 620 Current provisions 953 847 Other current liabilities 12 697 6 7694 Trade payables 6 76 944 6 57 60	Cash and cash equivalent and Current financial assets	314 238	269 719
LIABILITIES Share capital 1759 1767 Preniums related to the share capital 420 682 448 388 Treasury share reserve (184) (239) Currency translation adjustment (1 631) (1 510) Retained earnings (137 188) (157 828) Not income (loss) (20 544) (257 19) Total shareholders' equity - Group Share 262 894 254 859 Non-controlling interests 725 1 166 Total shareholders' equity 263 619 256 024 Non-current liabilities 66 38 Non-current liabilities 66 38 Current provisions 437 565 Total non-current liabilities 66 38 Current financial liabilities 1 921 2 173 Trade payables 6 61 11 324 Deferred revenues and deferred income 54 758 44 620 Current liabilities 12 697 6 796 Trade payables 12 697 6 796 Deferred revenues and deferred income </td <td>Total current assets</td> <td>334 218</td> <td>305 173</td>	Total current assets	334 218	305 173
Shareholders' equity 1759 1767 Share capital 1759 1767 Premiums related to the share capital 420 682 443 388 Treasury share reserve (184) (239) Currency translation adjustment (1631) (157 028) Retained earnings (20 544) (35 719) Not income (loss) (20 544) (23 5719) Total shareholders' equity - Group Share 262 894 254 859 Non-controlling interests 725 1166 Non-current liabilities 725 126 Non-current liabilities 66 38 Non-current liabilities 66 38 Current liabilities 503 600 Current fiancial liabilities 1921 2173 Tade payables 6611 11324 Defered revenues and defered income 54 758 44 620 Current liabilities 1953 847 Other current liabilities 12697 6756 Other current liabilities 12697 67560	TOTAL ASSETS	341 062	322 387
Share capital 1759 1767 Premiums related to the share capital 420 682 448 388 Treasury share reserve (184) (20) Currency translation adjustment (1631) (1510) Retained earnings (137 188) (157 828) Net income (loss) (20 544) (25 858) Total shareholders' equity - Group Share 262 894 254 852 Non-controlling interests 725 1166 Total shareholders' equity 263 619 256 024 Non-current liabilities 66 38 Non-current liabilities 66 38 Non-current liabilities 503 603 Current provisions 437 565 Total on-current liabilities 1921 2173 Trade payables 66 611 11324 Deferred revenues and deferred income 54 758 44 620 Current liabilities 953 847 Other current liabilities 953 847 Other current liabilities 12 697 6796 Trade payables 611 11324 Defer	LIABILITIES		
Premiums related to the share capital 420 682 448 388 Treasury share reserve (184) (239) Currency translation adjustment (1 631) (1 510) Retained earnings (137 188) (157 828) Not income (loss) (20 544) (35 719) Total shareholders' equity - Group Share 263 894 254 859 Non-controlling interests 725 1166 Total shareholders' equity 263 619 2256 024 Non-current liabilities 66 38 Non-current financial liabilities 66 38 Non-current liabilities 66 38 Current timancial liabilities 661 31 Total non-current liabilities 1921 2173 Trade payables 6 611 11 324 Deferred revenues and deferred income 54 758 44 620 Current liabilities 953 847 Other current liabilities 953 647 Total urrent liabilities 953 647 Deferred revenues and deferred income 54 758 6420 Current liabilities 953			
Treasury share reserve (184) (239) Currency translation adjustment (1 631) (1 510) Retained earnings (137 188) (157 828) Net income (loss) (20 544) (35 719) Total shareholders' equity - Group Share 262 894 254 859 Non-controlling interests 725 1 166 Total shareholders' equity 263 619 256 024 Non-current liabilities 66 38 Non-current financial liabilities 66 38 Non-current liabilities 66 38 Non-current liabilities 661 11 324 Current financial liabilities 1 921 2 173 Trade payables 6 611 11 324 Deferred revenues and deferred income 54 758 44 620 Current liabilities 953 847 Other current liabilities 12 697 6 796 Total current liabilities 12 697 6 796			
Currency translation adjustment (1 631) (1 510) Retained earnings (137 188) (157 828) Net income (loss) (20 544) (35 719) Total shareholders' equity - Group Share 262 894 224 859 Non-controlling interests 725 1 166 Total shareholders' equity 263 619 256 024 Non-current liabilities 66 38 Non-current provisions 437 565 Total non-current liabilities 503 663 Current liabilities 1921 2 173 Trade payables 1921 2 173 Current provisions 1921 2 173 Trade payables 66 611 11 324 Deferred revenues and deferred income 54 758 44 620 Current liabilities 953 847 Other current liabilities 953 847 Other current liabilities 12 697 6 796 Total current liabilities 76 940 65 760			
Retained earnings (137 188) (157 828) Net income (loss) (20 544) (35 719) Total shareholders' equity - Group Share 262 894 254 859 Non-controlling interests 725 1 166 Total shareholders' equity 263 619 256 024 Non-current liabilities 66 38 Non-current financial liabilities 66 38 Non-current financial liabilities 66 38 Current financial liabilities 503 603 Current financial liabilities 1 921 2 173 Trade payables 6 611 11 324 Deferred revenues and deferred income 54 758 44 620 Current liabilities 953 847 Other current liabilities 953 6 676 Total current liabilities 12 697 6 796 Total current liabilities 12 697 6 796			
Net income (loss) (20 544) (35 719) Total shareholders' equity - Group Share 262 894 254 859 Non-controlling interests 725 1 166 Total shareholders' equity 263 619 256 024 Non-current liabilities 66 38 Non-current financial liabilities 66 38 Non-current provisions 433 555 Total non-current liabilities 603 603 Current liabilities 1 921 2 173 Trade payables 1 921 2 173 Current provisions 6 611 11 324 Deferred revenues and deferred income 553 847 Current liabilities 953 847 Current liabilities 12 697 6 796 Other current liabilities 12 697 6 796 Total current liabilities 76 940 6 5760			
Total shareholders' equity - Group Share262 894254 859Non-controlling interests7251 166Total shareholders' equity263 619256 024Non-current liabilities6638Non-current financial liabilities6638Non-current provisions437565Total non-current liabilities503603Current liabilities1 9212 173Trade payables661111 324Deferred revenues and deferred income54 75844 620Current liabilities953847Other current liabilities12 6976 796Total current liabilities12 6976 796Total current liabilities12 6976 796Total current liabilities12 6976 796			
Non-controlling interests7251 166Total shareholders' equity263 619256 024Non-current liabilities6638Non-current financial liabilities6638Non-current provisions6638Current liabilities6638Current liabilities603603Current liabilities19212 173Current financial liabilities19216 611Current financial liabilities19216 611Current financial liabilities19216 611Current revenues and deferred income54 768444Current revenues and deferred income54 763Current liabilities12 6976 796Total current liabilities76 94065 760		()	
Total shareholders' equity263 619256 024Non-current liabilities6638Non-current financial liabilities6638Non-current provisions437565Total non-current liabilities503603Current liabilities19212173Current financial liabilities661111 324Current financial liabilities661111 324Current financial liabilities661111 324Current provisions953847Other current liabilities12 6976 796Total current liabilities76 94065 760			
Non-current liabilitiesNon-current financial liabilitiesNon-current provisionsNon-current provisionsCurrent liabilitiesCurrent liabilitiesCurrent liabilitiesCurrent financial liabilitiesCurrent liabilities<			
Non-current financial liabilities6638Non-current provisions437565Total non-current liabilities503603Current liabilities19212173Current financial liabilities661111324Current financial liabilities661111324Deferred revenues and deferred income5475844 620Current liabilities953847Other current liabilities12 6976 796Total current liabilities76 94065 760	iotai shareholuers' equity	203 013	230 024
Non-current provisions437565Total non-current liabilities503603Current liabilities21732173Current financial liabilities9212173Trade payables6611111324Deferred revenues and deferred income54758444 620Current provisions953847Other current liabilities12 6976 796Total current liabilities76 94065 760		66	20
Total non-current liabilities503603Current liabilities1 9212 173Current financial liabilities1 9212 173Trade payables6 61111 324Deferred revenues and deferred income54 75844 620Current provisions953847Other current liabilities12 6976 796Total current liabilities76 94065 760			
Current financial liabilities 1 921 2 173 Trade payables 6 611 11 324 Deferred revenues and deferred income 54 758 44 620 Current provisions 953 847 Other current liabilities 12 697 6 796 Total current liabilities 76 940 65 760	•		
Current financial liabilities 1 921 2 173 Trade payables 6 611 11 324 Deferred revenues and deferred income 54 758 44 620 Current provisions 953 847 Other current liabilities 12 697 6 796 Total current liabilities 76 940 65 760	Current lightlities		
Trade payables 6 611 11 324 Deferred revenues and deferred income 54 758 44 620 Current provisions 953 847 Other current liabilities 12 697 6 796 Total current liabilities 76 940 65 760		1 921	2 173
Deferred revenues and deferred income 54 758 44 620 Current provisions 953 847 Other current liabilities 12 697 6 796 Total current liabilities 76 940 65 760			
Current provisions 953 847 Other current liabilities 12 697 6 796 Total current liabilities 76 940 65 760			
Other current liabilities12 6976 796Total current liabilities76 94065 760			
	•		
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY 341 062 322 387	Total current liabilities	76 940	65 760
	TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY	341 062	322 387

CELLECTIS S.A.

STATEMENT OF CONSOLIDATED OPERATIONS – SECOND QUARTER

(unaudited) (€ in thousands, except per share data)

		For the three-month period ended June 30,	
	2015	2016	
Revenues and other income			
Revenues	7 328	15 823	
Other income	676	2 317	
Total revenues and other income	8 004	18 140	
	0 004	10 140	
Operating expenses and other operating income (expenses)			
Royalty expenses	(392)	(291)	
Research and development expenses (1)	(12 782)	(19 526)	
Selling, general and administrative expenses (1)	(6 865)	(8 600)	
Other operating income	166	264	
Redundancy plan	28	0	
Other operating expenses	(285)	(8)	
Total operating expenses and other operating income (expenses)	(20 130)	(28 158)	
Operating income (loss)	(12 126)	(10 018)	
Financial gain (loss)	(10 039)	3 763	
Net income (loss)	(22 166)	(6 255)	
Attributable to shareholders of Cellectis	(22 166)	(6 255)	
Attributable to non-controlling interests	· · ·	-	
Basic earnings attributable to shareholders of Cellectis per share (€/share)	(0,63)	(0,18)	
Diluted earnings attributable to shareholders of Cellectis per share (€/share)	(0,63)	(0,18)	

(1) Cellectis reclassified certain expenses related to the year ended December 31, 2015 from SG&A expenses to R&D expenses in the fourth quarter of 2015. This reclassification is effective starting in 2015, and is due to the increased level of efforts towards our R&D activities in order to develop product candidates and work toward clinical phases. Starting in 2015, we classify personnel and other costs related to information technology, human resources, business development, legal, intellectual property and general management in Research and development expense based on the time that employees spent contributing to research and development activities versus general and administrative activities. We approved the reclassification in Q4 2015 and assess the performance of the consolidated company based on this new classification.

CELLECTIS S.A.

STATEMENT OF CONSOLIDATED OPERATIONS - FIRST HALF-YEAR (unaudited) (€ in thousands, except per share data)

		For the six-month period ended June 30,	
	2015	2016	
Revenues and other income			
Revenues	15 756	22 801	
Other income	13750	4 838	
Total revenues and other income	17 223	27 639	
Total revenues and other income	17 225	27 035	
Operating expenses and other operating income (expenses)			
Royalty expenses	(819)	(723)	
Research and development expenses (1)	(20 218)	(38 396)	
Selling, general and administrative expenses (1)	(12 225)	(19 127)	
Other operating income	516	386	
Redundancy plan	235	1	
Other operating expenses	(397)	(206)	
Total operating expenses and other operating income (expenses)	(32 907)	(58 066)	
Operating income (loss)	(15 684)	(30 427)	
Financial gain (loss)	(166)	(5 292)	
Net income (loss)	(15 850)	(35 719)	
Attributable to shareholders of Cellectis	(16 020)	(35 719)	
Attributable to snarrhouters of cenecus Attributable to non-controlling interests	(10 020)	(55715)	
	1/1		
Basic earnings attributable to shareholders of Cellectis per share (€/share)	(0,48)	(1,01)	
	<u>_</u>	<u> </u>	
Diluted earnings attributable to shareholders of Cellectis per share (€/share)	(0,48)	(1,01)	
- • • •			

(1) Cellectis reclassified certain expenses related to the year ended December 31, 2015 from SG&A expenses to R&D expenses in the fourth quarter of 2015. This reclassification is effective starting in 2015, and is due to the increased level of efforts towards our R&D activities in order to develop product candidates and work toward clinical phases. Starting in 2015, we classify personnel and other costs related to information technology, human resources, business development, legal, intellectual property and general management in Research and development expense based on the time that employees spent contributing to research and development activities versus general and administrative activities. We approved the reclassification in Q4 2015 and assess the performance of the consolidated company based on this new classification.

Note Regarding Use of Non-GAAP Financial Measures

Cellectis S.A. presents Adjusted Income (Loss) attributable to shareholders of Cellectis in this press release. Adjusted Income (Loss) attributable to shareholders of Cellectis is not a measure calculated in accordance with IFRS. We have included in this press release a reconciliation of this figure to Net Income (Loss) attributable to shareholders of Cellectis, the most directly comparable financial measure calculated in accordance with IFRS. Because Adjusted Income (Loss) attributable to shareholders of Cellectis excludes Non-cash stock-based compensation expense—a non-cash expense, we believe that this financial measure, when considered together with our IFRS financial statements, can enhance an overall understanding of Cellectis' financial performance. Moreover, our management views the Company's operations, and manages its business, based, in part, on this financial measure. In particular, we believe that the elimination of Non-cash stock-based expenses from Net Income (Loss) attributable to shareholders of Cellectis can provide a useful measure for period-to-period comparisons of our core businesses. Our use of Adjusted Income (Loss) attributable to shareholders of Cellectis has limitations as an analytical tool, and you should not consider it in isolation or as a substitute for analysis of our financial results as reported under IFRS. Some of these limitations are: (a) other companies, including companies in our industry which use similar stock-based compensation, may address the impact of Non-cash stock-based compensation expense differently; and (b) other companies may report Adjusted Income (Loss) attributable to shareholders or similarly titled measures but calculate them differently, which reduces their usefulness as a comparative measure. Because of these and other limitations, you should consider Adjusted Income (Loss) attributable to shareholders of Cellectis alongside our IFRS financial results, including Net Income (Loss) attributable to shareholders of Cellectis.

RECONCILIATION OF GAAP TO NON-GAAP NET INCOME – Second quarter (unaudited) (€ in thousands, except per share data)

	For the three-month period ended June 30,	
	2015	2016
Net Income (Loss) attributable to shareholders of Cellectis Adjustment:	(22 166)	(6 255)
Non-cash stock-based compensation expense	7 178	14 383
Adjusted Income (Loss) attributable to shareholders of Cellectis	(14 988)	8 128
Basic Adjusted Income (Loss) attributable to shareholders of Cellectis (€/share)	(0,43)	0,23
Weighted average number of outstanding shares, basic (units)	35 043 251	35 295 817
Diluted Adjusted Income (Loss) attributable to shareholders of Cellectis (€/share)	(0,43)	0,23
Weighted average number of outstanding shares, diluted (units)	35 211 737	35 472 312

RECONCILIATION OF GAAP TO NON-GAAP NET INCOME - First half-year (unaudited) (1

		indiance)	
(€ in	thousands,	except per	share data)

	For the six-month period ended June 30,	
	2015	2016
Net Income (Loss) attributable to shareholders of Cellectis Adjustment:	(16 020)	(35 719)
Non-cash stock-based compensation expense	8 017	27 797
Adjusted Income (Loss) attributable to shareholders of Cellectis	(8 003)	(7 922)
Basic Adjusted Income (Loss) attributable to shareholders of Cellectis (€/share)	(0,24)	(0,22)
Weighted average number of outstanding shares, basic (units)	33 181 535	35 245 549
Diluted Adjusted Income (Loss) attributable to shareholders of Cellectis (€/share)	(0,24)	(0,22)
Weighted average number of outstanding shares, diluted (units)	33 505 001	35 622 858

As a foreign private issuer, we are not required under the Exchange Act to file periodic reports and financial statements with the SEC as frequently or as promptly as United States companies whose securities are registered under the Exchange Act. Notwithstanding the foregoing, we currently provide quarterly interim consolidated financial data to the SEC, and commencing with our first quarter interim report for the 2017 fiscal year, we intend to file our periodic reports within the deadlines applicable to domestic reporting companies.

About Cellectis

Cellectis is a biopharmaceutical company focused on developing immunotherapies based on gene edited CAR T-cells (UCART). The company's mission is to develop a new generation of cancer therapies based on engineered T-cells. Cellectis capitalizes on its

16 years of expertise in genome engineering - based on its flagship TALEN[®] products and meganucleases and pioneering electroporation PulseAgile technology - to create a new generation of immunotherapies. CAR technologies are designed to target surface antigens expressed on cells. Using its life-science-focused, pioneering genome-engineering technologies, Cellectis' goal is to create innovative products in multiple fields and with various target markets. Cellectis is listed on the Nasdaq market (ticker: CLLS) and on the NYSE Alternext market (ticker: ALCLS). To find out more about us, visit our website: <u>www.cellectis.com</u>

Talking about gene editing? We do it.

TALEN[®] is a registered trademark owned by the Cellectis Group.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains certain "forward - looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by words such as "anticipate," "believe," "can," "could," "estimate," "expect," "intend," "is designed to," "may," "might," "plan," "potential," "predict," "objective," "should," or the negative of these and similar expressions and include, but are not limited to, statements regarding the outlook for Cellectis' future business and financial performance. Forward-looking statements are based on management's current expectations and assumptions, which are subject to inherent uncertainties, risks and changes in circumstances, many of which are beyond Cellectis' control. Actual outcomes and results may differ materially due to global political, economic, business, competitive, market, regulatory and other factors and risks. Cellectis expressly disclaims any obligation to update or revise any of these forward-looking statements, whether because of future events, new information, a change in its views or expectations, or otherwise.

CONTACT:

Media contacts Jennifer Moore, +1 917-580-1088 VP Communications media@cellectis.com or Caitlin Kasunich, +1 212-896-1241 KCSA Strategic Communications ckasunich@kcsa.com or Investor relations contact: Simon Harnest, +1 646-385-9008 VP Corporate Strategy and Finance

simon.harnest@cellectis.com